Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Rahsaan ThompsonChief Legal & Compliance | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 06/22 | 06/23 | 34,557 sh | $12.68 | $438,182.76 | −30.1% |
Rahsaan ThompsonChief Legal & Compliance | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 05/11 | 05/13 | 1,794 sh | $11.30 | $20,272.2 | −3.6% |
Neil F. McFarlanePresident and CEO | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 02/09 | 02/10 | 14,625 sh | $8.56 | $125,190 | −3.6% |
Timothy J. SangiovanniSVP, Finance & Corp Controller | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 02/03 | 02/04 | 3,000 sh | $9.18 | $27,540 | −9.2% |
Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 02/03 | 02/04 | 10,500 sh | $9.19 | $96,495 | −14.4% | |
Neil F. McFarlanePresident and CEO | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 02/02 | 02/02 | 91,000 sh | $9.38 | $853,580 | −20.0% |
Timothy J. SangiovanniSVP, Finance & Corp Controller | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 01/30 | 02/02 | 1,750 sh | $8.82 | $15,435 | −7.7% |
Rahsaan ThompsonChief Legal & Compliance | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 01/30 | 02/02 | 4,080 sh | $8.83 | $36,026.4 | −7.6% |
Adrian W. QuartelChief Medical Officer | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 01/30 | 02/02 | 4,533 sh | $8.83 | $40,026.39 | −31.8% |
Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 01/30 | 02/02 | 3,375 sh | $8.83 | $29,801.25 | −8.3% | |
Neil F. McFarlanePresident and CEO | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 25/10/10 | 25/10/10 | 19,500 sh | $10.82 | $210,990 | −8.1% |
Tamara A. FavoritoDirector | Zevra TherapeuticsZVRA | Open-market buy | 25/09/12 | 25/09/16 | 3,175 sh | $7.79 | $24,733.25 | +441.6% |
Alvin ShihDirector | Zevra TherapeuticsZVRA | Open-market buy | 25/09/12 | 25/09/15 | 20,000 sh | $7.89 | $157,800 | No record |
John B. BodeDirector | Zevra TherapeuticsZVRA | Open-market buy | 25/08/19 | 25/08/20 | 5,000 sh | $9.17 | $45,850 | +12.5% |
Rahsaan ThompsonChief Legal & Compliance | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 25/06/26 | 25/06/30 | 24,000 sh | $9.21 | $221,040 | −36.0% |
Corey Michael WattonDirector | Zevra TherapeuticsZVRA | Open-market buy | 25/03/28 | 25/03/31 | 300 sh | $7.84 | $2,352 | +20.0% |
John B. BodeDirector | Zevra TherapeuticsZVRA | Open-market buy | 25/03/19 | 25/03/21 | 10,000 sh | $7.96 | $79,600 | +33.3% |
Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 25/02/13–25/02/14 | 25/02/14 | 91,817 sh2 trades | $7.92avg. | $727,484.98 | −32.4% | |
R. Laduane CliftonCFO & Treasurer | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 25/02/13 | 25/02/14 | 11,000 sh | $7.86 | $86,460 | −17.6% |
Timothy J. SangiovanniSVP, Finance & Corp Controller | Zevra TherapeuticsZVRA | Open-market sale10b5-1 plan | 25/02/13 | 25/02/14 | 3,000 sh | $7.86 | $23,580 | −15.5% |